294 related articles for article (PubMed ID: 25213852)
1. Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease.
Antoniu SA
Expert Opin Ther Targets; 2014 Nov; 18(11):1285-92. PubMed ID: 25213852
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
Gür ZT; Çalışkan B; Banoglu E
Eur J Med Chem; 2018 Jun; 153():34-48. PubMed ID: 28784429
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies for asthma and chronic obstructive pulmonary disease.
Antoniu SA
Expert Opin Biol Ther; 2013 Feb; 13(2):257-68. PubMed ID: 23282002
[TBL] [Abstract][Full Text] [Related]
4. Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome.
Nakawah MO; Hawkins C; Barbandi F
J Am Board Fam Med; 2013; 26(4):470-7. PubMed ID: 23833163
[TBL] [Abstract][Full Text] [Related]
5. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).
Banoglu E; Çelikoğlu E; Völker S; Olgaç A; Gerstmeier J; Garscha U; Çalışkan B; Schubert US; Carotti A; Macchiarulo A; Werz O
Eur J Med Chem; 2016 May; 113():1-10. PubMed ID: 26922224
[TBL] [Abstract][Full Text] [Related]
6. Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma?
Beeh KM; Beier J
Clin Exp Allergy; 2006 Feb; 36(2):142-57. PubMed ID: 16433851
[TBL] [Abstract][Full Text] [Related]
7. Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease.
Brusselle G; Bracke K
Ann Am Thorac Soc; 2014 Dec; 11 Suppl 5():S322-8. PubMed ID: 25525740
[TBL] [Abstract][Full Text] [Related]
8. Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.
Barnes PJ
Pharmacol Rev; 2016 Jul; 68(3):788-815. PubMed ID: 27363440
[TBL] [Abstract][Full Text] [Related]
9. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
Pergola C; Gerstmeier J; Mönch B; Çalışkan B; Luderer S; Weinigel C; Barz D; Maczewsky J; Pace S; Rossi A; Sautebin L; Banoglu E; Werz O
Br J Pharmacol; 2014 Jun; 171(12):3051-64. PubMed ID: 24641614
[TBL] [Abstract][Full Text] [Related]
10. Structure-based drug design on membrane protein targets: human integral membrane protein 5-lipoxygenase-activating protein.
Ferguson AD
Methods Mol Biol; 2012; 841():267-90. PubMed ID: 22222457
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-9 as a possible therapeutic target in both asthma and chronic obstructive airways disease.
McNamara PS; Smyth RL
Drug News Perspect; 2005 Dec; 18(10):615-21. PubMed ID: 16491163
[TBL] [Abstract][Full Text] [Related]
12. Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models.
Baker KE; Bonvini SJ; Donovan C; Foong RE; Han B; Jha A; Shaifta Y; Smit M; Johnson JR; Moir LM
Pulm Pharmacol Ther; 2014 Dec; 29(2):181-98. PubMed ID: 24929072
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Page CP
Int Arch Allergy Immunol; 2014; 165(3):152-64. PubMed ID: 25532037
[TBL] [Abstract][Full Text] [Related]
14. Recent advances for FLAP inhibitors.
Pettersen D; Davidsson Ö; Whatling C
Bioorg Med Chem Lett; 2015 Jul; 25(13):2607-12. PubMed ID: 26004579
[TBL] [Abstract][Full Text] [Related]
15. Similarities and differences in asthma and chronic obstructive pulmonary disease exacerbations.
Pauwels RA
Proc Am Thorac Soc; 2004; 1(2):73-6. PubMed ID: 16113416
[TBL] [Abstract][Full Text] [Related]
16. Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle.
Catley MC; Sukkar MB; Chung KF; Jaffee B; Liao SM; Coyle AJ; Haddad el-B; Barnes PJ; Newton R
Mol Pharmacol; 2006 Aug; 70(2):697-705. PubMed ID: 16687566
[TBL] [Abstract][Full Text] [Related]
17. Current and future therapies for airway mucus hypersecretion.
Barnes PJ
Novartis Found Symp; 2002; 248():237-49; discussion 249-53, 277-82. PubMed ID: 12568498
[TBL] [Abstract][Full Text] [Related]
18. Bedoradrine for treating asthma and chronic obstructive pulmonary disease.
Antoniu S
Expert Opin Investig Drugs; 2014 Aug; 23(8):1149-56. PubMed ID: 24938936
[TBL] [Abstract][Full Text] [Related]
19. Asthma & COPD--IQPC's Second Conference.
Catley MC
IDrugs; 2010 Sep; 13(9):601-4. PubMed ID: 20799138
[TBL] [Abstract][Full Text] [Related]
20. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
Doukas J; Eide L; Stebbins K; Racanelli-Layton A; Dellamary L; Martin M; Dneprovskaia E; Noronha G; Soll R; Wrasidlo W; Acevedo LM; Cheresh DA
J Pharmacol Exp Ther; 2009 Mar; 328(3):758-65. PubMed ID: 19056934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
